Abstract
HIF-1-mediated adaptation to changes in oxygen availability is a critical aspect of healthy physiology. HIF is regulated by a conserved mechanism whereby EGLN/PHD family members hydroxylate HIF in an oxygen-dependent manner, targeting it for ubiquitination by Von-Hippel-Lindau (VHL) family members, leading to its proteasomal degradation. The activity of the only C. elegans PHD family member, EGL-9, is also regulated by a hydrogen sulfide sensing cysteine-synthetase-like protein, CYSL-1, which is, in turn, regulated by RHY-1/acyltransferase. Over the last decade multiple seminal studies have established a role for the hypoxic response in regulating longevity, with mutations in vhl-1 substantially extending C. elegans lifespan through a HIF-1-dependent mechanism. However, studies on other components of the hypoxic signaling pathway that similarly stabilize HIF-1 have shown more mixed results, suggesting that mutations in egl-9 and rhy-1 frequently fail to extend lifespan. Here, we show that egl-9 and rhy-1 mutants suppress the long-lived phenotype of vhl-1 mutants. We also show that RNAi of rhy-1 extends lifespan of wild-type worms while decreasing lifespan of vhl-1 mutant worms. We further identify VHL-1-independent gene expression changes mediated by EGL-9 and RHY-1 and find that a subset of these genes contributes to longevity regulation. The resulting data suggest that changes in HIF-1 activity derived by interactions with EGL-9 likely contribute greatly to its role in regulation of longevity.
Introduction
Adaptation to changes in oxygen availability is a central requirement for aerobic life. In response to hypoxia, reduced oxygen-dependent hydroxylation of Hypoxia Inducible Factor α (HIFα) transcription factors by members of the EGLN/Proline-Hydroxylase (PHD) family triggers stabilization of HIFα proteins and activation of a transcriptional stress response that promotes survival (Epstein et al., 2001). This hypoxic response plays critical roles in a variety of pathological conditions including inflammation and cancer (Balamurugan, 2016; Pezzuto & Carico, 2018; Ramakrishnan & Shah, 2016). Constitutive stabilization of the sole C. elegans HIFα family member, HIF-1, by deletion of the Von-Hippel-Lindau ubiquitin ligase, VHL-1, which ubiquitinates HIF-1 and targets it for degradation, results in HIF-1-dependent increases in stress response and longevity (Cockman et al., 2000; Jiang et al., 2001; Leiser & Kaeberlein, 2010; Mehta et al., 2009; Müller et al., 2009; Treinin et al., 2003; Zhang et al., 2009).
Genetic studies in C. elegans have identified additional players in the hypoxic signaling pathway. Activity of EGL-9, the only known C. elegans PHD family member, is inhibited by direct interaction with the H2S sensing cysteine-synthetase family member CYSL-1 (Ma et al., 2012). CYSL-1 protein levels are in turn reduced through an unknown mechanism by Regulator of Hypoxia-inducible factor-1 (RHY-1), an ER transmembrane protein with predicted acyltransferase activity (Ma et al., 2012; Shen et al., 2006). Predicted loss-of-function mutations in rhy-1 stabilize HIF-1 and produce expression patterns of HIF-1 target genes that are consistent with reduced EGL-9 activity (Shen et al., 2006).
Interestingly, while vhl-1 mutation extends C. elegans lifespan across culture conditions, the role of EGL-9/PHD is more context dependent. While egl-9(RNAi) extends lifespan at 20°C, the lifespan phenotypes of partial loss-of-function mutations in egl-9 are temperature-dependent, extending lifespan in a HIF-1-dependent manner at low temperatures (15°C) but not at higher temperatures (20°C and 25°C) (Leiser et al., 2011; Leiser & Kaeberlein, 2010; Miller et al., 2017; Zhang et al., 2009). The loss-of-function mutant egl-9(sa307) also reduces the lifespan of dietary restricted animals and long-lived rsks-1 mutants when animals are cultured at 25°C, suggesting that EGL-9 activity may promote lifespan in multiple contexts (Di Chen & Kapahi, 2009). Furthermore, recent work from our lab showed that rhy-1 putative knockout mutants were not long-lived at any temperature, despite their reported robust activation of hypoxic response genes (Miller et al., 2017; Shen et al., 2006).
Previous studies on the roles of EGL-9, RHY-1, and VHL-1 show that 1) HIF-1 stabilization when vhl-1 is mutated leads to robust induction of egl-9 and rhy-1, 2) EGL-9 and RHY-1 have VHL-1-independent effects on transcription of some hypoxic response genes, and 3) EGL-9 and RHY-1 play a VHL-1-independent role in pathogen and hydrogen sulfide resistance (Horsman et al., 2019; Luhachack et al., 2012; Shao et al., 2009; Shao et al., 2010; Shen et al., 2005; Shen et al., 2006). However, the possibility that EGL-9 and RHY-1 modulate longevity through a downstream, VHL-1-independent transcriptional response has not been addressed. Here we present a genetic study demonstrating that EGL-9 and RHY-1 are necessary for lifespan extension when HIF-1 is stabilized by vhl-1 mutation. We show that, like EGL-9, RHY-1 has both longevity promoting and inhibiting activities. We further identify genes that are oppositely regulated in vhl-1 and egl-9 or rhy-1 mutants, suggesting that RHY-1 and EGL-9 promote a VHL-1-independent transcriptional response when HIF-1 is stabilized by vhl-1 mutation. Lastly, we find that RNAi knockdown of four genes downregulated in vhl-1(ok161) mutants and upregulated in egl-9(sa307) mutants, with likely functions in innate immunity, each partially rescues lifespan extension in egl-9(sa307);vhl-1(ok161) mutants. Together, our results suggest that EGL-9 modulates lifespan by regulating a VHL-1-independent transcriptional program.
Results
RHY-1 and EGL-9 promote longevity in vhl-1 mutants
We initially hypothesized that the presence of EGL-9 and RHY-1 is necessary to promote longevity downstream of HIF-1 stabilization. This hypothesis would suggest that reduced activity of EGL-9 or RHY-1 would prevent or mitigate lifespan extension when HIF-1 is stabilized by reducing VHL-1 activity. Previous studies show that vhl-1 and egl-9 mutant strains show similar lifespan phenotypes at low temperatures (15°C), making epistasis experiments difficult to interpret (Miller et al., 2017). However, at high temperatures, egl-9(sa307) mutants have short to wild-type lifespans while vhl-1(ok161) mutants are long-lived (Di Chen & Kapahi, 2009; Leiser et al., 2011; Miller et al., 2017). Thus, we tested whether egl-9(sa307) and/or rhy-1(ok1402) mutants suppress the extended longevity phenotype of vhl-1(RNAi)-treated or vhl-1(ok161) mutant animals at high temperature (25°C). Our results (Figure 1) show that rhy-1(ok1402) (Fig. 1A) and egl-9(sa307) (Fig. 1B) mutants abrogate the extended longevity phenotype caused by vhl-1(RNAi) at 25°C. Furthermore, rhy-1(ok1402) fully abrogated the extended longevity phenotype of vhl-1(ok161) mutants (Fig. 1C), while egl-9(sa307) mutants partially suppressed the extended longevity phenotype vhl-1(ok161) mutants at 25°C (Fig. 1D). We also observed that rhy-1(RNAi) reduces the lifespan of vhl-1 mutants at low temperatures (15°C, (Fig. 1E)) and that the lifespan of rhy-1(ok1402) mutants are not extended by vhl-1(RNAi) at low temperatures (15°C, (Fig. S1)), suggesting that these interactions are not fully temperature-dependent. These results are consistent with a model where RHY-1 and EGL-9 act in the same pathway to promote lifespan downstream of HIF-1 stabilization.
RHY-1 has longevity promoting and inhibiting activities
In the course of testing the effects of rhy-1(RNAi) on vhl-1(ok161) mutants at 15°C, we observed that rhy-1(RNAi) substantially extended the lifespan of wild-type control animals (Fig. 2A). This result was surprising since we recently reported a study of the interaction between temperature and longevity and found that rhy-1(ok1402) mutants did not extend lifespan at any of the three temperatures (15°C, 20°C, or 25°C) that are commonly used for longevity studies (Miller et al., 2017). We outcrossed rhy-1(ok1402) five additional times to wild-type to further eliminate any background mutations and repeated lifespan experiments. Consistent with our published data, the outcrossed rhy-1(ok1402) strain was not long-lived: observed lifespans were modestly longer than wild-type in two of four trials, identical to wild-type in one trial, and shorter than wild-type in one trial (Fig. 2B, S1). Lifespan extension by rhy-1(RNAi) was abrogated by rhy-1(ok1402), consistent with the longevity extension phenotype caused by rhy-1(RNAi) being dependent on modulation of the RHY-1 gene product (Fig. 2C). Furthermore, rhy-1(RNAi) treated cysl-1(ok762) and hif-1(ia4) mutants are short lived relative to rhy-1(RNAi) treated wild-type animals, consistent with a model where HIF-1 and CYSL-1 activity are required for full lifespan extension by rhy-1(RNAi) (Fig. 2D-E). Importantly, rhy-1(RNAi) treatment does extend the lifespans of cysl-1(ok762) and hif-1(ia4) mutants relative to vector treated controls (Figure 2 D,E) suggesting that it may modulate lifespan through a mechanism that is partially independent of the CYSL-1, HIF-1 pathway. The distinct phenotypes observed in rhy-1(ok1402) and rhy-1(RNAi) are similar to the reported differences between egl-9(RNAi), which extends lifespan at 20°C, and the egl-9(sa307) mutant, which extends lifespan at 15°C but not 20°C or 25°C (Di Chen & Kapahi, 2009; Mehta et al., 2009; Miller et al., 2017; Zhang et al., 2009). These results are consistent with a model where partial reductions in activity of rhy-1 or egl-9 increase longevity by stabilizing HIF-1, while stronger reduction of rhy-1 or egl-9 causes a secondary effect that limits lifespan downstream of HIF-1 stabilization.
RHY-1 and EGL-9 control a VHL-1-independent transcriptional response
Previous studies reported that egl-9 causes vhl-1-independent changes in expression of some transcripts (Shao et al., 2009; Shen et al., 2005; Shen et al., 2006). We hypothesized that the dominance of the egl-9(sa307) and rhy-1(ok1402) lifespan phenotypes over the vhl-1(ok161) lifespan phenotype might be caused by genes whose transcription is regulated by EGL-9 or RHY-1. Concurrently with our work, Angeles et al. published an analysis of transcriptome profiles from rhy-1(ok1402), egl-9(sa307), hif-1(ia4), egl-9;hif-1, and egl-9;vhl-1 mutants. They identified a class of genes whose transcription is regulated by EGL-9 in a way that is distinct from, and dominant over, their regulation by VHL-1. We will refer to this class as EGL-9/VHL-1 antagonistic genes.
To identify genes that might modulate lifespan downstream of the hypoxic response, we had previously profiled the transcriptomes of egl-9(sa307), vhl-1(ok161), rhy-1(ok402), and hif-1(ia4) mutants. We reanalyzed our data using the methodology that Angeles et al. reported and an up-to-date bioinformatic pipeline (Angeles-Albores et al., 2018; Bray et al., 2016; Pimentel et al., 2017). Our datasets identified a subset of genes that were differentially expressed in the HIF-1 negative regulator mutants relative to wild-type, further confirming that these changes are implicated in the hypoxic response, (Fig. 3A, Table 1, Table S3,S4). Conversely, we observed low overlap between the datasets for genes differentially expressed in the hif-1(ia4) background, suggesting that differences between hif-1(ia4) and wild-type in individual datasets may largely reflect strain-specific effects rather than HIF-1-dependent transcription under normoxia (Fig 3B).
We next plotted β coefficients of differentially expressed genes shared between vhl-1(ok161) and egl-9(sa307) in Leiser and Sternberg datasets (Fig 3C). Both datasets produce a similar pattern, with egl-9(sa307), and vhl-1(ok161) causing highly correlated changes in expression for most shared differentially expressed genes. Both datasets also contained EGL-9/VHL-1 antagonistic genes, which were either upregulated in vhl-1(ok161) and downregulated in egl-9(sa307) (Fig. 3C, quadrant II), or upregulated in egl-9(sa307) or rhy-1(ok1402) and downregulated in vhl-1(ok161) (Fig. 3C, quadrant IV). The genes in quadrants II and IV, who we hypothesized could play a role in different outcomes between vhl-1(ok161) and egl-9(sa307) or rhy-1(ok1402) strains, are listed in Table S5. Together, our and the Sternberg lab’s results show that HIF-1 stabilization through loss of its negative regulators has both many common effects and a smaller number of opposing effects depending on which negative regulator is mutated.
Knockdown of egl-9 target genes rescues lifespan egl-9(sa307);vhl-1(ok161) mutants
We next tested the hypothesis that EGL-9/VHL-1 antagonistic genes regulate longevity. Previous results suggest that individual longevity-pathway-target-genes often have small effects on lifespan, and longevity increases are more likely than longevity decreases to reflect modulation of the aging process as a whole (Murphy et al., 2003). Thus, we identified candidate EGL-9/VHL-1 antagonistic genes whose downregulation in vhl-1(ok161) mutants was reversed in egl-9(sa307);vhl-1(ok161) mutants and determined whether RNAi targeting them could extend life lifespan of egl-9;vhl-1(ok161) mutants (Figure 4 A,C,E,G, Table S6).
EGL-9 and VHL-1 have distinct roles in pathogen resistance, with egl-9(sa307) mutants exhibiting HIF-1-dependent resistance to fast killing by pseudomonas aeruginosa while vhl-1(ok161) mutants do not (Luhachack et al., 2012; Shao et al., 2010). We noticed that our list of EGL-9/VHL-1 antagonistic genes contained several genes with reported or predicted roles in pathogen response, including nlp-31, which encodes five neuropeptide-like proteins with functions in defense against fungal pathogens and gram-negative pathogenic bacteria, lys-7, which encodes a lysozyme with a reported role in defense against gram-negative bacteria, lys-10, which encodes another lysozyme, and lips-10, which encodes an enzyme that, like lysozymes, has hydrolase activity (Couillault et al., 2004; Harris et al., 2010; Marsh et al., 2011; Nathoo et al., 2001). We found that treatment with lys-10(RNAi), lips-10(RNAi), lys-7(RNAi), and nlp-31(RNAi) each extended longevity of egl-9;vhl-1 mutants (Fig. 4 B,D,F,H).
We also tested treatment with RNAi targeting the ferritin genes, ftn-1 and ftn-2, predicted oxidative and heavy metal response genes that have been identified as EGL-9/VHL-1 antagonistic genes in multiple studies (Ackerman & Gems, 2012; Romero-Afrima et al., 2020). We found slight but significant increases in lifespan in egl-9(sa307);vhl-1(ok161) animals treated with ftn-1(RNAi) and ftn-2(RNAi), however the magnitude of these changes was small and they were not consistent across individual replicates (significant in 2 of 4 trials) (Figure S2 and Table S2). These data are consistent with ferritins playing a minor role in modulation of lifespan by the hypoxic response.
Taken together, these results are consistent with a model in which EGL-9 activity promotes longevity during HIF-1 stabilization through VHL-1-independent inhibition of target genes, including multiple genes with predicted functions in defense against pathogens.
Discussion
Collectively, our results show that, while reduction in RHY-1 and EGL-9 activity can increase lifespan via the hypoxic response, RHY-1 and EGL-9 activity also promote longevity downstream of HIF-1 stabilization by vhl-1 mutation. We further demonstrate that RHY-1 and EGL-9 activity are required to control the direction of differential expression of numerous transcripts in vhl-1 mutants and that EGL-9-dependent suppression of nlp-31, lys-7, lys-10, and lips-10 promotes longevity in vhl-1 mutants.
Genetic interactions of vhl-1, egl-9, and rhy-1
While HIF has emerged as a key regulator of longevity, it was previously unknown how hypoxic signaling pathway components interact to influence longevity. HIF-1 hydroxylation is required for its interaction with VHL-1, so in theory we might expect egl-9 mutant phenotypes to be epistatic to vhl-1 mutant phenotypes. However, reports that 1) EGL-9 and RHY-1 have VHL-1-independent roles in the expression and tissue distribution of hypoxic response genes, 2) EGL-9 interacts with other proteins through proline-hydroxylase-activity-dependent and -independent mechanisms to influence phenotype, and 3) EGL-9 and RHY-1 are transcriptionally upregulated when HIF-1 is stabilized, make these phenotypic interactions difficult to predict (Luhachack et al., 2012; Shao et al., 2009; Shao et al., 2010; Shen et al., 2005; Shen et al., 2006).
We found that rhy-1(ok1402) blocked lifespan extension by vhl-1(RNAi) and vhl-1(ok161), while egl-9(sa307) blocked lifespan extension by vhl-1(RNAi) and partially blocked lifespan extension by vhl-1(ok161). While these results are broadly consistent with a model where RHY-1 regulates lifespan through its known EGL-9 modulating activity, it is interesting that rhy-1 mutation has a stronger effect on the longevity of vhl-1(ok161) mutants than the egl-9(sa307) mutation. This could be explained by the reportedly more robust HIF-1 stabilization and upregulation of pro-longevity HIF-1 target genes in egl-9(sa307) relative to rhy-1(ok1402), or by an additional, HIF-1-independent role for RHY-1 in longevity determination (Shen et al., 2006).
We confirmed the surprising, previously reported, result that the rhy-1(ok1402) mutation does not extend lifespan, despite stabilizing HIF-1. However, interestingly, rhy-1(RNAi) extends lifespan through a mechanism that is partially dependent on its established interactions with CYSL-1 and HIF-1. While off-target effects of RNAi are a concern when mutant and RNAi phenotypes differ, the observation that the rhy-1(RNAi)-mediated lifespan increase is fully abrogated in a rhy-1(ok1402) mutant background strongly suggests that modulation of RHY-1 is the primary factor influencing lifespan in this context. It is worth noting that, while cysl-1(ok762) and hif-1(ia4) mutations reduce the longevity promoting effect of rhy-1(RNAi), neither completely abrogates it. This suggests that RHY-1 may have secondary, HIF-1-independent roles that influence longevity. Published reports showing that rhy-1;hif-1 compound mutants have a synthetic deleterious effect on fertility and that RHY-1 modulates hydrogen-sulfide resistance in a HIF-1-independent manner also suggest interesting HIF-1-independent roles for RHY-1 (Horsman et al., 2019; Shen et al., 2006).
A published mechanism explaining the interaction between RHY-1 and HIF-1 suggests that rhy-1 mutants should largely phenocopy egl-9 mutants (Ma et al., 2012). While interpretation of egl-9 phenotypes is complicated by the lack of a viable egl-9 null mutant, published results do suggest that egl-9(n571), a point mutant that is predicted to affect splicing, and egl-9(RNAi) have more robust longevity promoting phenotypes than the strong loss-of-function mutant, egl-9(sa307), a deletion in the EGL-9 catalytic domain (Darby et al., 1999; Miller et al., 2017; Shao et al., 2009; Trent et al., 1983). These results are consistent with EGL-9 also having longevity promoting and limiting functions, with the mutant phenotype depending on the severity of the loss in activity. These data are consistent with a model in which EGl-9 and RHY-1 act in the same pathway to both limit wild-type longevity by destabilizing HIF-1 and increase longevity when HIF-1 is stabilized.
VHL-1-independent EGL-9 targets modulate lifespan
Along with other groups, we identified a substantial subset of targets that are transcriptionally regulated in opposite directions by EGL-9 and VHL-1 (Ackerman & Gems, 2012; Angeles-Albores et al., 2018). This suggests that upregulation of EGL-9 and RHY-1 when HIF-1 is stabilized has substantial effects on the hypoxic transcriptome in addition to possible feedback regulation of HIF-1. Previous publications have established that EGL-9 has VHL-1-independent activities that can increase or reduce resistance to various pathogens (Luhachack et al., 2012; Shao et al., 2010). Here, we find that several RNAi clones targeting genes with reported or likely functions in innate immunity, nlp-31(RNAi) lys-7(RNAi), lys-10(RNAi), and lips-10(RNAi), extend lifespan in egl-9(sa307);vhl-1(ok161) mutants, suggesting that EGL-9-dependent downregulation of these genes promotes longevity in vhl-1(ok161) mutants.
The mechanisms underlying VHL-1-independent transcriptional regulation by EGL-9 have not been fully established. Previous studies report that egl-9(sa307) and hif-1(ia4) loss of function mutants cause transcriptional upregulation of the direct HIF-1 transcriptional target ftn-1, while vhl-1 loss of function mutants and overexpression of non-hydroxylatable HIF-1 (P621A) suppress ftn-1 expression (Ackerman & Gems, 2012; Romero-Afrima et al., 2020). These results are consistent with a model in which binding of hydroxylated and non-hydroxylated HIF-1 may have opposite effects on the ftn-1 promoter region, with vhl-1(ok161) mutation causing increases in hydroxylated HIF-1 while hif-1(ia4) and egl-9(sa307) mutation both eliminate hydroxylated HIF-1 (Ackerman & Gems, 2012; Romero-Afrima et al., 2020). A recent analysis from the Sternberg group showed expression patterns consistent with a role for hydroxylated HIF-1 in expression of a larger set of transcripts that are oppositely affected by VHL-1 and EGL-9 (Angeles-Albores et al., 2018).
Other reports suggest that EGL-9 may trigger VHL-1-independent transcriptional responses through more complex mechanisms. Multiple labs report that EGL-9 affects gene expression through mechanisms that are independent of its hydroxylation activity (Luhachack et al., 2012; Shao et al., 2009). One study suggests that EGL-9 represses HIF-1 activity through a mechanism that requires physical interaction between EGL-9/PHD and the WD repeat containing protein SWAN-1 (Shao et al., 2010). EGL-9 might also affect gene expression via hydroxylation of substrates other than HIF-1, with one study indicating that LIN-10 is a target of EGL-9 hydroxylation (Park et al., 2012). Mechanistic biochemical studies to 1) identify EGL-9 hydroxylation targets and protein-protein interaction partners, and 2) establish whether hydroxylated and non-hydroxylated HIF-1 interact with distinct transcriptional complexes, will be needed to fully understand the complex biological function of EGL-9/PHD.
Constitutive sterile activation of the innate immune response increases during mammalian aging and is a key driver of many age-related pathologies (Franceschi & Campisi, 2014). A trade-off between constitutive immune activation and longevity has also been established in Drosophila (Libert et al., 2006). In C. elegans, immune-related signaling genes contribute to the longevity phenotypes of long-lived insulin signaling mutants; however, to our knowledge, this is the first evidence of antagonism between immune activation and non-pathogen exposed survival in C. elegans (Murphy et al., 2003). Further mechanistic studies of the connection between pathogen resistance genes and accelerated aging-related phenotypes in tractable model systems may yield insights and interventions that can be translated to mammalian inflammatory aging pathologies.
Conclusion
Drugs that inhibit PHD activity are currently in clinical trials for anemia, and animal studies have suggested that they may have efficacy in models of neurodegenerative conditions, indicating that modulation of the hypoxic response to treat age-related disorders in humans may be on the horizon (Ashok et al., 2017; Haase, 2017; Li et al., 2018; Mehta et al., 2009). However, the role of HIF-1 activity in modulating aging and age-related pathologies is highly complex. The finding that RHY-1 and EGL-9/PHD modulate aging by a VHL-1-independent mechanism indicates that further studies to illuminate the mechanisms underlying non-canonical roles of proline-hydroxylases in influencing transcription, aging, and disease will be critical to support effective translation of compounds that modulate the hypoxic response.
Methods
Worm culture and RNAi
Standard procedures for C. elegans strain maintenance and handling were used (Ahringer, 2006; Stiernagle, 2019). Experiments were performed on animals grown on Escherichia coli HT115 expressing empty vector or target RNAi from the Ahringer library. Nematode strains N2, rhy-1(ok1402), egl-9(sa307); vhl-1(ok161), hif-1(ia4), cysl-1(ok762) and egl-9(sa307);vhl-1(ok161) were obtained from the Caenorhabditis Genetics Center. rhy-1(ok1402) was outcrossed 5 times to a recently unfrozen CGC N2 strain, and rhy-1(ok1402);vhl-1(ok161) was made from outcrossed rhy-1(ok1402) using standard methods.
Lifespans
Lifespans were performed as described previously with minor modifications (Amrit et al., 2014). Animals were cultured on standard RNAi plates (NGM + 4ml 1M IPTG/L) inoculated with empty vector RNAi or the clone being tested, at the temperature of the assay, for at least two generations prior to measuring lifespans. Synchronized populations were transferred to lifespan plates (NGM+100mg Carbenecillin 4ml1M IPTG/l+660ul 150mM FUDR/L) at adulthood. Animals with age-related vulval integrity defects were included, animals that left the plate were not considered (Leiser et al., 2016). Replicates and statistics are included in supplemental table 1.
RNA isolation, sequencing and analysis
Worm strains were synchronized by treating gravid adult worms with sodium hypochlorite and collecting ~1000 offspring per genetic condition. Once the offspring reached young adulthood, they were collected in M9 buffer and immediately flash-frozen in liquid nitrogen. RNA was extracted following Invitrogen’s TRIZOL RNA extraction protocol. Before library preparation the samples were analyzed on an Agilent 2100 BioAnalyzer. Only samples with an RNA integrity numbers (RIN) equal to or greater than 9.0 were used in downstream analyses. Single-strand reverse transcription, library preparation, and sequencing were performed on an Illumina machine. Read alignments were mapped using Kallisto and differential expression analyses was performed using Sleuth. We used a q-value cutoff of <.05 for downstream comparisons across conditions as it’s adjusted for multiple hypothesis testing (Bray et al., 2016; Pimentel et al., 2017).
Acknowledgements
We thank David Angeles and the Sternberg lab for sharing their Kallisto analyses and expertise. This work was supported by NIH R01AG058717 and the Glenn Foundation for Medical Research. HAM was supported by NIH F31AG060663. Additionally, we thank the University of Washington Nathan Shock Center for support of gene expression analysis (NIH P30AG013280). Strains were provided by the Caenorhabditis Genetics Center that is funded by the NIH ORIP (P40OD010440).